TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05752747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Massage Group
Description: Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker© Group
Description: It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
Study: NCT05497297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 tablets
Description: HSK7653, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 tablets
Description: HSK7653, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 tablets
Description: HSK7653, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 tablets
Description: HSK7653, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 tablets
Description: HSK7653, tablet, oral
Study: NCT05161026

Intervention type: OTHER
Group type: OTHER
Intervention: Bone osteodensitometry
Description: Evaluation of bone osteodensitometry
Study: NCT06033547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Formulation G
Description: Cabotegravir Formulation G will be administered
Study: NCT06056518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based risk prediction for kidney graft loss
Description: Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
Study: NCT06432543

Intervention type: DEVICE
Intervention: polyethylene
Description: No intervention as this is an observational study

Intervention type: DEVICE
Intervention: polyethylene
Description: No intervention as this is an observational study

Intervention type: DEVICE
Intervention: polyethylene
Description: No intervention as this is an observational study
Study: NCT06474325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention via mobile application
Description: Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
Study: NCT06786689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine (AZA)
Description: weekly single dose of tab azathioprine 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: oral Betamethsone 5mg for 2 consecutive days weekly
Study: NCT06784089

Intervention type: OTHER
Intervention: Geriatric Nutrition Risk Index
Description: GNRI will be calculated from the formula \[1.489 X albumin (g/L)\] + \[41.7 (weight/ideal weight)\]. If the patient's weight is more than their ideal weight, the weight/ideal weight ratio will be accepted as 1. The ideal weight will be calculated for men with the formula \[(Height-100) -(Height-150/4)\], for women with the formula \[(Height-100) -(Height-150/2.5)\]. According to the results, patients will be determined as no risk (GNRI \> 98), low risk (92-98), severe/moderate risk (GNRI \< 92).

Intervention type: OTHER
Intervention: visual analog scale
Description: During the VAS evaluation, the patient will be asked to indicate the location of the pain on a 100 cm long scale where 0: no pain, 100: maximum pain, and the value shown by the patient will be recorded.
Study: NCT06786429

Intervention type: BIOLOGICAL
Intervention: Gardasil 9 vaccine
Description: Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.

Intervention type: BIOLOGICAL
Intervention: Gardasil 9 vaccine
Description: Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.

Intervention type: BIOLOGICAL
Intervention: Hepatitis B Virus Vaccine(HBV)
Description: Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
Study: NCT06322277

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample
Description: Confermation of type of infection with RT-PCR.
Study: NCT04886297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mega Resveratrol® capsules
Description: Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mega Resveratrol® capsules
Description: Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mega Resveratrol® capsules
Description: Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mega Resveratrol® Placebo capsules
Description: Mega Resveratrol® Placebo capsules
Study: NCT05582876

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiopharmaceutical 68Ga-PSMA-11 PET/CT
Description: The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiopharmaceutical 68Ga-PSMA-11 PET/CT
Description: The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
Study: NCT06786429

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy
Description: Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy
Description: Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
Study: NCT05165719

Intervention type: DIAGNOSTIC_TEST
Intervention: Corona-T-test
Description: Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Corona-T-test
Description: Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Corona-T-test
Description: Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
Study: NCT05456243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Description: Single intra-arterial infusion of 1 x 10\^5 cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Description: Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes
Study: NCT06785701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Gastrointestinal Endoscopy
Description: After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Gastrointestinal Endoscopy
Description: After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.
Study: NCT06782646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
Study: NCT05373823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySmartSkin enhancement
Description: Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
Study: NCT06229041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab ＋Immunotherapy
Description: Camrelizumab was used in preoperative treatment.
Study: NCT05883163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimit Activator 1
Description: The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
Study: NCT05373823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational webpage on Skin Self-Examination
Description: Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assess implementation outcomes
Description: A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
Study: NCT06784895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women only Cardiac Rehab program
Description: This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry.~This group orientation prior to starting CR will allow additional time for enhanced story telling among patients, provide a more detailed description of what to expect in CR, and allow additional time to address participant concerns or worries prior to starting CR. Women-specific education content will be provided monthly in addition to the standard weekly mini-teaches. This education content will be developed and delivered by experience health care professionals that are experts in women's health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (mixed-sex) rehab program
Description: This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise.
Study: NCT06785415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06783205

Intervention type: OTHER
Intervention: Restriction of the Dominant Hand Due to Splint Use
Description: This study aimed to assess whether the non-dominant hand function changes in patients using splints or casts on their dominant hand during the tissue healing period.
Study: NCT06787807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy
Study: NCT06786533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-FLT3 CAR-T cells
Description: Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-FLT3 CAR-T cells
Description: Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-FLT3 CAR-T cells
Description: Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-FLT3 CAR-T cells
Description: Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.
Study: NCT06786377

Intervention type: GENETIC
Intervention: saliva sampling
Description: saliva sampling

Intervention type: GENETIC
Intervention: saliva sampling
Description: saliva sampling
Study: NCT06782477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0310
Description: STAR-0310 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0310
Description: STAR-0310 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0310
Description: STAR-0310 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0310
Description: STAR-0310 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0310
Description: STAR-0310 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a subcutaneous bolus injection.
Study: NCT06785298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/carbidopa
Description: A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/carbidopa
Description: A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
Study: NCT06782698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: The home-based program follows the National recommendations on Physical Exercise for Cancer Patients \[Bruno RC, 2023\]. It is logbook-guided and technology-enabled.~It consists of:~* Two initial supervised explanatory sessions, in the Physic and Rehabilitation Medicine Gym of our institution.~* Followed by 2 muscular training sessions + 3 additional periods of aerobic exercise per week in their home environment until the end of neoadjuvant treatment. Patients are given a logbook with instructions and a sports bracelet for heart rate monitoring.~The training sessions will be monitored by smartwatch heart rate measurements and self-notion of effort according to Borg Categorization \[Borg GA, 1982\] and recorded by the participants in the Mi Fitness application or an Exercise Diary.\[Nilsen TS, 2018\]

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of Healthy Physical Activity
Description: The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of Healthy Physical Activity
Description: The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist.
Study: NCT06785753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation Solution
Description: normal saline will be used as irrigation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation Solution
Description: normal saline will be used as irrigation solution
Study: NCT04793477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: instrumentation technique in pulpectomies
Description: comparison of three file systems for pulpectomies in primary molars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: instrumentation technique in pulpectomies
Description: comparison of three file systems for pulpectomies in primary molars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: instrumentation technique in pulpectomies
Description: comparison of three file systems for pulpectomies in primary molars
Study: NCT06132984

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance
Description: Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
Study: NCT05722743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony at HOME
Description: The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Institute on Aging Program
Description: Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging Home Safety and Alzheimer's Disease webpage.
Study: NCT05221320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: small molecule ERK 1/2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: small molecule ERK 1/2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Autophagy inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Autophagy inhibitor
Study: NCT06082726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA
Description: Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA
Description: Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.